Alqasmi M
J Clin Med. 2024; 13(21).
PMID: 39518670
PMC: 11547045.
DOI: 10.3390/jcm13216530.
Trouve P, Saint Pierre A, Ferec C
Int J Mol Sci. 2024; 25(17).
PMID: 39273547
PMC: 11394767.
DOI: 10.3390/ijms25179599.
Colegate S, Palipana A, Gecili E, Szczesniak R, Brokamp C
J Clin Transl Sci. 2024; 8(1):e94.
PMID: 39220818
PMC: 11362628.
DOI: 10.1017/cts.2024.532.
Hansen C, Breukelman A, Van den Bemt P, Zwitserloot A, van Dijk L, van Boven J
Eur Respir Rev. 2024; 33(173).
PMID: 39142708
PMC: 11322823.
DOI: 10.1183/16000617.0060-2024.
Bui S, Delhaes L, Dournes G, Reix P, Fayon M
Front Pediatr. 2023; 11:1243496.
PMID: 37635799
PMC: 10450029.
DOI: 10.3389/fped.2023.1243496.
The RISE study protocol: resilience impacted by positive stressful events for people with cystic fibrosis.
van der Heijden E, van den Bor R, van der Ent C, Nijhof S, van der Laan S
ERJ Open Res. 2023; 9(3).
PMID: 37313395
PMC: 10258717.
DOI: 10.1183/23120541.00535-2022.
Association of Oxygen Therapy with the Natural Disease Progression of Cystic Fibrosis: A Multi-State Model of the European Cystic Fibrosis Society Patient Registry.
Gambazza S, Orenti A, Pizzamiglio G, Zolin A, Colombo C, Laquintana D
Ther Clin Risk Manag. 2023; 19:255-267.
PMID: 36935771
PMC: 10022450.
DOI: 10.2147/TCRM.S391476.
The Status of Carbapenem Resistance in Cystic Fibrosis: A Systematic Review and Meta-Analysis.
Saadh M, Lohrasbi A, Ghasemian E, Hashemian M, Etemad A, Dargahi Z
Yale J Biol Med. 2022; 95(4):495-506.
PMID: 36568834
PMC: 9765336.
Barriers for Sports and Exercise Participation and Corresponding Barrier Management in Cystic Fibrosis.
Dillenhoefer S, Stehling F, Welsner M, Schlegtendal A, Sutharsan S, Olivier M
Int J Environ Res Public Health. 2022; 19(20).
PMID: 36293733
PMC: 9603748.
DOI: 10.3390/ijerph192013150.
Therapeutic applications of curcumin nanomedicine formulations in cystic fibrosis.
Quispe C, Herrera-Bravo J, Khan K, Javed Z, Semwal P, Painuli S
Prog Biomater. 2022; 11(4):321-329.
PMID: 35904711
PMC: 9626725.
DOI: 10.1007/s40204-022-00198-3.
Structural Characterization of Phosphopantetheine Adenylyl Transferase Ligand Interactions: Implications for Fragment-Based Drug Design.
Thomas S, McCarthy W, El Bakali J, Brown K, Kim S, Blaszczyk M
Front Mol Biosci. 2022; 9:880432.
PMID: 35712348
PMC: 9197168.
DOI: 10.3389/fmolb.2022.880432.
CFTR Modulators in People with Cystic Fibrosis: Real-World Evidence in France.
Regard L, Martin C, Burnet E, Da Silva J, Burgel P
Cells. 2022; 11(11).
PMID: 35681464
PMC: 9179538.
DOI: 10.3390/cells11111769.
New drugs in cystic fibrosis: what has changed in the last decade?.
Roda J, Pinto-Silva C, Silva I, Maia C, Almeida S, Ferreira R
Ther Adv Chronic Dis. 2022; 13:20406223221098136.
PMID: 35620188
PMC: 9128052.
DOI: 10.1177/20406223221098136.
Quantification of Cystic Fibrosis Lung Disease with Radiomics-based CT Scores.
Chassagnon G, Zacharaki E, Bommart S, Burgel P, Chiron R, Dangeard S
Radiol Cardiothorac Imaging. 2021; 2(6):e200022.
PMID: 33778637
PMC: 7977785.
DOI: 10.1148/ryct.2020200022.
Trainability of Health-Related and Motor Performance Fitness in Adults with Cystic Fibrosis within a 12-Month Partially Supervised Exercise Program.
Welsner M, Gruber W, Mellies U, Olivier M, Sutharsan S, Taube C
Pulm Med. 2021; 2021:5581812.
PMID: 33763240
PMC: 7964122.
DOI: 10.1155/2021/5581812.
Cystic fibrosis-related diabetes and lung disease: an update.
Prentice B, Jaffe A, Hameed S, Verge C, Waters S, Widger J
Eur Respir Rev. 2021; 30(159).
PMID: 33597125
PMC: 9488640.
DOI: 10.1183/16000617.0293-2020.
Cystic fibrosis-related diabetes onset can be predicted using biomarkers measured at birth.
Lin Y, Keenan K, Gong J, Panjwani N, Avolio J, Lin F
Genet Med. 2021; 23(5):927-933.
PMID: 33500570
PMC: 8105168.
DOI: 10.1038/s41436-020-01073-x.
Bridging the survival gap in cystic fibrosis: An investigation of lung transplant outcomes in Canada and the United States.
Stephenson A, Ramos K, Sykes J, Ma X, Stanojevic S, Quon B
J Heart Lung Transplant. 2021; 40(3):201-209.
PMID: 33386232
PMC: 7925420.
DOI: 10.1016/j.healun.2020.12.001.
The Changing Face of Cystic Fibrosis and Its Implications for Screening.
Naehrlich L
Int J Neonatal Screen. 2020; 6(3):54.
PMID: 33123635
PMC: 7570194.
DOI: 10.3390/ijns6030054.
Molecular Heterogeneity in Cystic Fibrosis.
Civan H, Seyhan S
J Pediatr Genet. 2020; 9(3):171-176.
PMID: 32714617
PMC: 7375840.
DOI: 10.1055/s-0040-1701646.
